{"pmid":32419748,"pmcid":"PMC7213028","title":"Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology.","text":["Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology.","Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic.","Ann Indian Acad Neurol","Bhatia, Rohit","Srivastava, M V Padma","Khurana, Dheeraj","Pandit, Lekha","Mathew, Thomas","Gupta, Salil","Netravathi, M","Nair, Sruthi S","Singh, Gagandeep","Singhal, Bhim S","32419748"],"abstract":["Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic."],"journal":"Ann Indian Acad Neurol","authors":["Bhatia, Rohit","Srivastava, M V Padma","Khurana, Dheeraj","Pandit, Lekha","Mathew, Thomas","Gupta, Salil","Netravathi, M","Nair, Sruthi S","Singh, Gagandeep","Singhal, Bhim S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419748","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.4103/0972-2327.282442","keywords":["covid 19","mog","ms","nmosd","disease modifying therapy","immunotherapy"],"topics":["Prevention"],"weight":1,"_version_":1667254896654548992,"score":9.490897,"similar":[{"pmid":32419749,"pmcid":"PMC7213027","title":"Consensus Statement - Suggested Recommendations for Acute Stroke Management during the COVID-19 Pandemic: Expert Group on Behalf of the Indian Stroke Association.","text":["Consensus Statement - Suggested Recommendations for Acute Stroke Management during the COVID-19 Pandemic: Expert Group on Behalf of the Indian Stroke Association.","The ongoing pandemic of COVID-19 is a global public health emergency. This has led to challenges for healthcare facilities to optimally manage other important medical emergencies. Stroke is an important public health emergency with significant mortality and morbidity. Timely treatment of acute stroke is critical to prevent disability. The current expert consensus statement on behalf of the Indian Stroke Association outlines the issues and suggestions related to the management of stroke during this ongoing COVID-19 pandemic.","Ann Indian Acad Neurol","Bhatia, Rohit","Sylaja, P N","Srivastava, M V Padma","Khurana, Dheeraj","Pandian, Jeyaraj Durian","Suri, Vinit","Kumar, V G Pradeep","Kumaravelu, S","Huded, Vikram","Surya, Nirmal","Sharma, Arvind","Kaul, Subhash","32419749"],"abstract":["The ongoing pandemic of COVID-19 is a global public health emergency. This has led to challenges for healthcare facilities to optimally manage other important medical emergencies. Stroke is an important public health emergency with significant mortality and morbidity. Timely treatment of acute stroke is critical to prevent disability. The current expert consensus statement on behalf of the Indian Stroke Association outlines the issues and suggestions related to the management of stroke during this ongoing COVID-19 pandemic."],"journal":"Ann Indian Acad Neurol","authors":["Bhatia, Rohit","Sylaja, P N","Srivastava, M V Padma","Khurana, Dheeraj","Pandian, Jeyaraj Durian","Suri, Vinit","Kumar, V G Pradeep","Kumaravelu, S","Huded, Vikram","Surya, Nirmal","Sharma, Arvind","Kaul, Subhash"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419749","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.4103/aian.AIAN_302_20","keywords":["acute stroke","covid-19","ischemic stroke","thrombectomy","thrombolysis"],"topics":["Prevention"],"weight":1,"_version_":1667254896789815296,"score":160.18832},{"pmid":32299636,"pmcid":"PMC7136883","title":"Should we expect neurological symptoms in the SARS-CoV-2 epidemic?","text":["Should we expect neurological symptoms in the SARS-CoV-2 epidemic?","INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS.","Neurologia","Matias-Guiu, J","Gomez-Pinedo, U","Montero-Escribano, P","Gomez-Iglesias, P","Porta-Etessam, J","Matias-Guiu, J A","32299636"],"abstract":["INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS."],"journal":"Neurologia","authors":["Matias-Guiu, J","Gomez-Pinedo, U","Montero-Escribano, P","Gomez-Iglesias, P","Porta-Etessam, J","Matias-Guiu, J A"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299636","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.nrl.2020.03.001","keywords":["central nervous system","coronavirus","esclerosis multiple","mers-cov","mouse hepatitis virus","multiple sclerosis","neurological symptoms","sars-cov","sars-cov-2","sistema nervioso central","sintomas neurologicos","virus murino de la hepatitis"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494861312001,"score":129.24843},{"pmid":32440979,"title":"Assessing disability and relapses in multiple sclerosis on tele-neurology.","text":["Assessing disability and relapses in multiple sclerosis on tele-neurology.","BACKGROUND: As a consequence of the coronavirus disease 2019 (COVID-19) pandemic, a large amount of consultations will be delivered through tele-medicine, especially for diseases causing chronic disability and requiring immunomodulatory treatments, such as multiple sclerosis (MS). METHODS: We have hereby reviewed available tools for tele-neurology examination in MS, including components of neurological examination that can be assessed through video, patient-reported outcome measures (PROMs), and digital technology. RESULTS: Overall, we have suggested a battery for assessing MS disability and relapses on tele-medicine, which brings together conventional examination, PROMs (e.g., Patient Determined Disease Steps, MS Impact Scale), and cognitive tests (Symbol Digit Modalities Test) that can be delivered remotely and in multiple languages. DISCUSSION: The use of common tools for neurological examination could improve tele-neurology practice for both general neurologists and MS specialists, and quality of care for people with MS.","Neurol Sci","Moccia, Marcello","Lanzillo, Roberta","Brescia Morra, Vincenzo","Bonavita, Simona","Tedeschi, Gioacchino","Leocani, Letizia","Lavorgna, Luigi","32440979"],"abstract":["BACKGROUND: As a consequence of the coronavirus disease 2019 (COVID-19) pandemic, a large amount of consultations will be delivered through tele-medicine, especially for diseases causing chronic disability and requiring immunomodulatory treatments, such as multiple sclerosis (MS). METHODS: We have hereby reviewed available tools for tele-neurology examination in MS, including components of neurological examination that can be assessed through video, patient-reported outcome measures (PROMs), and digital technology. RESULTS: Overall, we have suggested a battery for assessing MS disability and relapses on tele-medicine, which brings together conventional examination, PROMs (e.g., Patient Determined Disease Steps, MS Impact Scale), and cognitive tests (Symbol Digit Modalities Test) that can be delivered remotely and in multiple languages. DISCUSSION: The use of common tools for neurological examination could improve tele-neurology practice for both general neurologists and MS specialists, and quality of care for people with MS."],"journal":"Neurol Sci","authors":["Moccia, Marcello","Lanzillo, Roberta","Brescia Morra, Vincenzo","Bonavita, Simona","Tedeschi, Gioacchino","Leocani, Letizia","Lavorgna, Luigi"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440979","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s10072-020-04470-x","keywords":["covid","multiple sclerosis","tele-medicine","tele-neurology"],"topics":["Prevention"],"weight":1,"_version_":1667523504884416513,"score":118.68385},{"pmid":32241953,"title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.","text":["Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.","The emergence of novel Coronavirus 2019 (COVID-19)(1) and the subsequent pandemic present a unique challenge to Neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD).","Neurology","Brownlee, Wallace","Bourdette, Dennis","Broadley, Simon","Killestein, Joep","Ciccarelli, Olga","32241953"],"abstract":["The emergence of novel Coronavirus 2019 (COVID-19)(1) and the subsequent pandemic present a unique challenge to Neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD)."],"journal":"Neurology","authors":["Brownlee, Wallace","Bourdette, Dennis","Broadley, Simon","Killestein, Joep","Ciccarelli, Olga"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241953","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1212/WNL.0000000000009507","topics":["Prevention"],"weight":1,"_version_":1666138492112994305,"score":114.10577},{"pmid":32387786,"title":"Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community.","text":["Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community.","BACKGROUND: The coronavirus disease of 2019 (COVID-19) that is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been designated a pandemic by the World Health Organization, affecting 2.7 million individuals globally as of April 25, 2020 with over 187,000 deaths. A growing body of evidence supports central nervous system (CNS) involvement. METHODS: We conducted a review of the literature for articles concerning COVID-19 pathophysiology, neurological manifestations, and neuroscience provider recommendations and guidelines. RESULTS: CNS manifestations range from vague non-focal complaints to severe neurologic impairment associated with encephalitis. It is unclear whether neurological dysfunction is due to direct viral injury or systemic disease. The virus may affect brainstem pathways that lead to indirect respiratory dysfunction in addition to direct pulmonary injury. Necessary adaptations in patient management, triage, and diagnosis are evolving in light of ongoing scientific and clinical findings. CONCLUSIONS: This review consolidates the current body of literature regarding the neurological impact of coronaviruses, discusses the reported neurologic manifestations of COVID-19, and highlights recommendations for patient management. Specific recommendations pertaining to clinical practice for neurologists and neurosurgeons are provided.","World Neurosurg","Werner, Cassidy","Scullen, Tyler","Mathkour, Mansour","Zeoli, Tyler","Beighley, Adam","Kilgore, Mitchell D","Carr, Christopher","Zweifler, Richard M","Aysenne, Aimee","Maulucci, Christopher M","Dumont, Aaron S","Bui, Cuong J","Keen, Joseph R","32387786"],"abstract":["BACKGROUND: The coronavirus disease of 2019 (COVID-19) that is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been designated a pandemic by the World Health Organization, affecting 2.7 million individuals globally as of April 25, 2020 with over 187,000 deaths. A growing body of evidence supports central nervous system (CNS) involvement. METHODS: We conducted a review of the literature for articles concerning COVID-19 pathophysiology, neurological manifestations, and neuroscience provider recommendations and guidelines. RESULTS: CNS manifestations range from vague non-focal complaints to severe neurologic impairment associated with encephalitis. It is unclear whether neurological dysfunction is due to direct viral injury or systemic disease. The virus may affect brainstem pathways that lead to indirect respiratory dysfunction in addition to direct pulmonary injury. Necessary adaptations in patient management, triage, and diagnosis are evolving in light of ongoing scientific and clinical findings. CONCLUSIONS: This review consolidates the current body of literature regarding the neurological impact of coronaviruses, discusses the reported neurologic manifestations of COVID-19, and highlights recommendations for patient management. Specific recommendations pertaining to clinical practice for neurologists and neurosurgeons are provided."],"journal":"World Neurosurg","authors":["Werner, Cassidy","Scullen, Tyler","Mathkour, Mansour","Zeoli, Tyler","Beighley, Adam","Kilgore, Mitchell D","Carr, Christopher","Zweifler, Richard M","Aysenne, Aimee","Maulucci, Christopher M","Dumont, Aaron S","Bui, Cuong J","Keen, Joseph R"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387786","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.wneu.2020.04.222","keywords":["covid-19","encephalitis","guideline","neuroscience","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1666428892612657152,"score":113.92887}]}